These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

312 related articles for article (PubMed ID: 33356500)

  • 1. Targeting BRAF-Mutant Biliary Tract Cancer: Recent Advances and Future Challenges.
    Rizzo A; Federico AD; Ricci AD; Frega G; Palloni A; Pagani R; Tavolari S; Marco MD; Brandi G
    Cancer Control; 2020; 27(1):1073274820983013. PubMed ID: 33356500
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative Genomic Analysis and Clinical Outcomes of BRAF-mutated Advanced Biliary Tract Cancers.
    Tang TY; Nichetti F; Kaplan B; Lonardi S; Pietrantonio F; Salvatore L; Vivaldi C; Rimassa L; de Braud F; Rizzato MD; Pavlick D; Chu R; Danner De Armas A; Sharaf R; Sokol E; Rodon Ahnert J; Ross JS; Javle M; Niger M
    Clin Cancer Res; 2023 Dec; 29(23):4853-4862. PubMed ID: 37773629
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dabrafenib plus trametinib in patients with BRAF
    Subbiah V; Lassen U; Élez E; Italiano A; Curigliano G; Javle M; de Braud F; Prager GW; Greil R; Stein A; Fasolo A; Schellens JHM; Wen PY; Viele K; Boran AD; Gasal E; Burgess P; Ilankumaran P; Wainberg ZA
    Lancet Oncol; 2020 Sep; 21(9):1234-1243. PubMed ID: 32818466
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Systemic treatment of advanced or recurrent biliary tract cancer.
    Zhang W; Zhou H; Wang Y; Zhang Z; Cao G; Song T; Zhang T; Li Q
    Biosci Trends; 2020 Nov; 14(5):328-341. PubMed ID: 32830166
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeted therapies in advanced biliary tract cancers-a narrative review.
    LaPelusa M; Heumann T; Goff L; Agarwal R
    Chin Clin Oncol; 2023 Apr; 12(2):14. PubMed ID: 36946186
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase II study of uracil-tegafur plus doxorubicin and prognostic factors in patients with unresectable biliary tract cancer.
    Furuse J; Okusaka T; Ohkawa S; Nagase M; Funakoshi A; Boku N; Yamao K; Yamaguchi T; Sato T
    Cancer Chemother Pharmacol; 2009 Dec; 65(1):113-20. PubMed ID: 19404641
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gemcitabine-based chemotherapy for advanced biliary tract carcinomas.
    Abdel-Rahman O; Elsayed Z; Elhalawani H
    Cochrane Database Syst Rev; 2018 Apr; 4(4):CD011746. PubMed ID: 29624208
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current and emerging therapies for advanced biliary tract cancers.
    Kam AE; Masood A; Shroff RT
    Lancet Gastroenterol Hepatol; 2021 Nov; 6(11):956-969. PubMed ID: 34626563
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Systemic therapy for biliary tract cancers.
    Hezel AF; Zhu AX
    Oncologist; 2008 Apr; 13(4):415-23. PubMed ID: 18448556
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinicopathological and prognostic significances of EGFR, KRAS and BRAF mutations in biliary tract carcinomas in Taiwan.
    Chang YT; Chang MC; Huang KW; Tung CC; Hsu C; Wong JM
    J Gastroenterol Hepatol; 2014 May; 29(5):1119-25. PubMed ID: 24372748
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular Characterization of Biliary Tract Cancer Predicts Chemotherapy and Programmed Death 1/Programmed Death-Ligand 1 Blockade Responses.
    Yoon JG; Kim MH; Jang M; Kim H; Hwang HK; Kang CM; Lee WJ; Kang B; Lee CK; Lee MG; Chung HC; Choi HJ; Park YN
    Hepatology; 2021 Oct; 74(4):1914-1931. PubMed ID: 33884649
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recent advances of immunotherapy for biliary tract cancer.
    Rizzo A; Ricci AD; Brandi G
    Expert Rev Gastroenterol Hepatol; 2021 May; 15(5):527-536. PubMed ID: 33215952
    [No Abstract]   [Full Text] [Related]  

  • 13. Revolutionizing anti-HER2 therapies for extrahepatic cholangiocarcinoma and gallbladder cancer: Current advancements and future perspectives.
    Ten Haaft BH; Pedregal M; Prato J; Klümpen HJ; Moreno V; Lamarca A
    Eur J Cancer; 2024 Mar; 199():113564. PubMed ID: 38266541
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Landscape of distant metastasis mode and current chemotherapy efficacy of the advanced biliary tract cancer in the United States, 2010-2016.
    Wang J; Bo X; Nan L; Wang CC; Gao Z; Suo T; Ni X; Liu H; Lu P; Wang Y; Liu H
    Cancer Med; 2020 Feb; 9(4):1335-1348. PubMed ID: 31876990
    [TBL] [Abstract][Full Text] [Related]  

  • 15. First-line Chemotherapy in Advanced Biliary Tract Cancer Ten Years After the ABC-02 Trial: "And Yet It Moves!".
    Rizzo A; Brandi G
    Cancer Treat Res Commun; 2021; 27():100335. PubMed ID: 33592561
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular Features and Targeted Therapies in Extrahepatic Cholangiocarcinoma: Promises and Failures.
    Rizzo A; Tavolari S; Ricci AD; Frega G; Palloni A; Relli V; Salati M; Fenocchio E; Massa A; Aglietta M; Brandi G
    Cancers (Basel); 2020 Nov; 12(11):. PubMed ID: 33158162
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current options and future directions of systemic therapy for advanced biliary tract cancer.
    Prete MG; Cammarota A; D'Alessio A; Zanuso V; Rimassa L
    Explor Target Antitumor Ther; 2021; 2(5):416-433. PubMed ID: 36045701
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination of dabrafenib plus trametinib for BRAF and MEK inhibitor pretreated patients with advanced BRAF
    Schreuer M; Jansen Y; Planken S; Chevolet I; Seremet T; Kruse V; Neyns B
    Lancet Oncol; 2017 Apr; 18(4):464-472. PubMed ID: 28268064
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comprehensive review of the diagnosis and treatment of biliary tract cancer 2012. Part I: diagnosis-clinical staging and pathology.
    Marsh Rde W; Alonzo M; Bajaj S; Baker M; Elton E; Farrell TA; Gore RM; Hall C; Nowak J; Roy H; Shaikh A; Talamonti MS
    J Surg Oncol; 2012 Sep; 106(3):332-8. PubMed ID: 22488652
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nivolumab: an investigational agent for the treatment of biliary tract cancer.
    Di Federico A; Rizzo A; Ricci AD; Frega G; Palloni A; Tavolari S; Brandi G
    Expert Opin Investig Drugs; 2021 Apr; 30(4):325-332. PubMed ID: 33307866
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 16.